Rappta Therapeutics
Develops first-in-class anti-cancer molecular glues that reactivate the tumor suppressor PP2A, for oncology drug development
Highlights
- New on EvolcAdded 2026-10-28
About Rappta Therapeutics
Rappta Therapeutics is a late preclinical stage biopharmaceutical company. It is developing a series of small-molecule molecular glues that reactivate protein phosphatase 2A (PP2A), a tumor suppressor, with the aim of creating a new class of anti-cancer drugs.
The company describes its proprietary tools and understanding of PP2A biology as the basis for its compounds, and states that the approach has platform potential for a broad range of diseases.
Rappta was founded in 2019 and is headquartered in Helsinki, Finland. Its team is based in Finland and the United States.
Product: Small-molecule compounds (molecular glues) that reactivate PP2A for anti-cancer drug development
Jobs at Rappta Therapeutics
More biotech & pharma companies
Reagena
Diagnostic tests and laboratory reagents for clinical, biotechnology, pharmaceutical and research organizationsNew on EvolcReBio Technologies
Develops targeted, locally delivered drug conjugates for ocular cancers, starting with uveal melanomaNew on EvolcReplicon Health
Develops oral drug candidate RH013001 for aging-related degenerative diseases and seeks pharma partners to bring it to marketNew on EvolcRNatives
Develops RNA-based gene-regulating therapies for serious diseases, with research and offices in Kuopio, FinlandNew on EvolcSartar Therapeutics
Develops targeted cancer therapies for patients with gastrointestinal stromal tumours and other cancersNew on EvolcScaffdex
Finnish maker of the RegJoint bioresorbable small-joint implant and CellCrown cell culture inserts for clinicians and researchersNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Cookiebot
- Google Universal Analytics
- WordPress
- jQuery
- nginx